<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04086914</url>
  </required_header>
  <id_info>
    <org_study_id>00090054</org_study_id>
    <nct_id>NCT04086914</nct_id>
  </id_info>
  <brief_title>Fascia Iliaca Compartment Blocks for Pain Control in Hip Fractures</brief_title>
  <official_title>Fascia Iliaca Compartment Blocks to Improve Preoperative Pain Control in Elderly Hip Fractures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is comparing the use of a peripheral nerve block and standard opioid pain
      medications in pain control in hip fractures prior to surgery. A peripheral nerve block is a
      procedure that injects numbing medicine around a nerve to help decrease the pain, motion, and
      sensation around the painful site temporarily. The purpose of this study is to evaluate if
      peripheral nerve blocks are more effective for pain control than just standard opioid pain
      medication while decreasing the amount of side effects from opioid medication.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study withdrawn at PI's request. no patients enrolled.
  </why_stopped>
  <start_date type="Anticipated">February 1, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Baseline Pain score on Visual analogue scale at initial encounter</measure>
    <time_frame>0-60 minutes</time_frame>
    <description>pain is measured 1-10, 1 being the lowest and 10 being the highest</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change from baseline pain score on the visual analogue scale</measure>
    <time_frame>3-8 hours after initial encounter</time_frame>
    <description>pain is measured 1-10, 1 being the lowest and 10 being the highest</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Hip Fractures</condition>
  <arm_group>
    <arm_group_label>Non nerve block</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Receives no nerve block</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nerve block</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Receives nerve block</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Nerve Block</intervention_name>
    <description>This group will receive a nerve block consisting of 20mL of 5mg/mL ropivicanine and 0.1mL of 10mg'mL dexamethasone.</description>
    <arm_group_label>Nerve block</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 50 or older, low energy hip fracture, acute hip fracture

        Exclusion Criteria:

          -  On anticoagulants, hardware present near injection site, preexisting nerve injury.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>September 10, 2019</study_first_submitted>
  <study_first_submitted_qc>September 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 12, 2019</study_first_posted>
  <last_update_submitted>February 4, 2020</last_update_submitted>
  <last_update_submitted_qc>February 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Hip Fractures</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

